Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse

27 Jun 2019
Nigel P Murray, Sócrates Aedo, Ricardo Villalon, Marco Antonio Lopez, Simona Minzer, Lorena Muñoz, Shenda Orrego, Luis Contreras, Lucas Arzeno, Eghon Guzman

Introduction: 25% of Stage III colon cancer patients relapse within 5 years due to minimal residual disease (MRD) not eliminated by surgery and chemotherapy. We hypothesise that sub-types of MRD, defined by circulating tumour cells (CTCs) and bone marrow micro-metastasis (mM) have different types and kinetics of relapse.

Patients and Methods: One month of curative surgery and 1 month after completing six cycles of FOLFOX chemotherapy blood and bone marrow samples were taken to detect CTCs and mM using immunocytochemistry with anti-carcino-embryonic antigen (CEA). Follow up was up to 5 years or disease progression defined as new images on CT scanning. Survival curves using Kaplan–Meier (KM) and Restricted Mean Survival Time (RMST) were calculated for three prognostic groups: CTC and mM negative, CTC negative mM positive, and CTC positive.

Results: 76 patients (39 men) participated, mean age 67 years, median follow-up 3.6 years. The response to chemotherapy was heterogeneous and MRD pre-treatment did not predict response to therapy. Of 21 patients MRD (−), 20 remained MRD negative and one patient became mM ( ); of 21 patients mM ( ), 10 became MRD (−), 8 remained the same and 3 became CTC ( ); of the 34 CTC positive, 8 became MRD (−), 8 with only mM, and 18 remained positive.

After chemotherapy, 38 patients were negative for CTC and mM, 17 were positive for only mM, and 21 for CTCs. For the whole cohort, the 5 year KM was 58%, the median survival was not reached. For the three prognostic groups, the KM 5-year survivals were 87%, 58%, and 4%, respectively, the median survival for patients MRD negative and mM only was not reached. RMST for the whole cohort was 3.6 years, for the three prognostic groups the RMST was 4.6 years, 4.0 years, and 1.5 years, respectively. Serum CEA was significantly higher pre-surgery in the CTC positive group. There were no significant differences with respect to age or sex between the three groups.

Conclusions: MRD subtypes pre-chemotherapy did not predict treatment response. Post-chemotherapy MRD subtypes were associated with the pattern of failure and time to failure. MRD negative patients had an excellent prognosis with 87% disease-free survival at 5 years. Those with only mM had a similar outcome up to 2 years and then were at increasing risk of late failure. Patients who were CTC positive had a high risk of early failure. MRD subclassification may be useful to define the risk of relapse in Stage III colon cancer patients and warrants further studies with a larger number of patients.

Article metrics: 672 views

Related Articles

Nigel P Murray, Sócrates Aedo, Cynthia Fuentealba, Eduardo Reyes, Aníbal Salazar, Eghon Guzman, Shenda Orrego
Luca Nicosia, Federica Ferrari, Anna Carla Bozzini, Antuono Latronico, Chiara Trentin, Lorenza Meneghetti, Filippo Pesapane, Maria Pizzamiglio, Nicola Balesetreri, Enrico Cassano
Sushmita Gordhandas, Ryan M Kahn, Charlotte Gamble, Nizam Talukdar, Brandon Maddy, Becky Baltich Nelson, Gulce Askin, Paul J Christos, Kevin Holcomb, Thomas A Caputo, Eloise Chapman-Davis, Melissa K Frey
Luis Larrea, Enrique López, Paola Antonini, Verónica González, Miguel Ángel Berenguer, Maria Carmen Baños, Jose Bea, Jose Domingo
Rachel P Riechelmann, Renata D’Alpino Peixoto, Gustavo Dos Santos Fernandes, Rui F Weschenfelder, Gabriel Prolla, Duilio Rocha Filho, Aline Chaves Andrade, Marcela Crosara, Juliana Florinda M Rego, Rene C Gansl, Felipe Coimbra, Samuel Aguiar Jr, Elisângela Carvalho, Paulo M Hoff, Anelisa K Coutinho